Previous 10 | Next 10 |
NOVATO, Calif., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today reported its financial results and corporate update for the quart...
ACHC , AEL , AKCA , ANDE , APLE , APTS , ATRO , ATUS , AVD , AWR , BE , BHF , BKD , BKH , BKNG , CAR , CBT , CDEV , COHU , CRZO , CTRE , CXW , DCO , DCP , DRH , DVAX , ELF , EVBG , FMC , FN , FNV , FRGI , FRPT , FTDR , HHC , IFF , INSY , IPAR , ITRI , ...
NOVATO, Calif., Oct. 30, 2018 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call on Monday, November...
Recently, Ultragenyx Pharmaceutical ( RARE ) announced that it had failed to meet the primary endpoint of a phase 3 study . This phase 3 study used a drug known as UX007 treating a rare genetic disorder known as Glucose Transporter Type 1 Deficiency Syndrome or Glut1DS. While the results ...
Ultragenyx Pharmaceuticals (NASDAQ: RARE ) announces positive results from its ongoing Phase 1/2 clinical trial evaluating gene therapy DTX301 in patients with a urea cycle disorder called ornithine transcarbamylase (OTC) deficiency. More news on: Ultragenyx Pharmaceutical Inc., Healthca...
Ureagenesis normalized in one patient in Cohort 2 Cohort 1 responder demonstrated continued biochemical improvement and clinical stability at Week 52 Higher-dose Cohort 3 patient enrollment to begin in 2018; data expected in mid-2019 NOVATO, Calif., Sept. 27, 2018 (GLOBE NEWSWI...
NEW YORK, NY / ACCESSWIRE / September 6, 2018 / Major U.S. equities were mixed on Wednesday with tech stocks posting worst daily drop since July dragging Nasdaq lower. The Dow Jones Industrial Average was up 0.09 percent to close at 25,974.99, while the S&P 500 Index decreased 0.28 percen...
The Nasdaq's selloff notwithstanding, most gene therapy stocks are in the red. This morning, Sangamo Therapeutics ( SGMO -21.1% ) reported data on SB-913 that disappointed investors. More news on: Sangamo Therapeutics, Inc., AVROBIO, MeiraGTx Holdings plc, Healthcare stocks news, Stocks ...
LONDON , September 5, 2018 /PRNewswire/ -- The positive recommendation marks a step change in the management of XLH for children and young people, and the first s ignificant clinical advancement for the condition in the last 35 years. The National Ins...
NOVATO, Calif., Aug. 30, 2018 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Shalini Sharp, the Company's Chief Financial Officer, will present...
News, Short Squeeze, Breakout and More Instantly...
Ultragenyx Pharmaceutical Inc. Company Name:
RARE Stock Symbol:
NASDAQ Market:
Ultragenyx Pharmaceutical Inc. Website:
NOVATO, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today announced that it will host a conference call at 5...
NOVATO, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the company will share the latest clinical data, regulatory progress and program next steps for GTX-102, its investigational antisense oligonucleotide for Angelman syndrome, on Wed...
2024-07-24 04:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...